| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Other Events
Announcement that Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at American Association for the Study of Liver Diseases (“AASLD”) |
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
–Q3 2026 net product sales of $185.7 million; 2026 net product sales guidance increased to $715 million to $720 million |
| 26 Oct 2026 |
8-K: Other Events
Announcement of Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva |
| 13 Oct 2026 |
8-K: Other Events
On October 12, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) announced topline results from the Phase 3 EXPAND study evaluating LIVMARLI (maralixibat) (“Livmarli”) for the treatment of cholestatic pruritus in patients aged 6 months o... |
| 28 Sep 2026 |
8-K: Other Events
On September 25, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) and Incyte Corporation (“Incyte”) announced that the U.S. Food and Drug Administration (“FDA”) approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total ne... |
| 08 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 8, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) announced that, on September 2, 2026, the Company’s Board of Directors appointed Rob Myers, M.D., to succeed Joanne Quan, M.D., as the Company’s Chief Medical Officer, eff... |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
–2026 net product sales guidance increased to $680 million to $700 million |
| 18 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 15, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 20, 2026, the record date for the Annual Meeting, 60,977,841 shares of the Company’s common st... |
| 18 May 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
INDENTURE, dated as of May 15, 2026, between Mirum Pharmaceuticals, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
–2026 net product sales guidance increased to $660 to $680 million |
| 04 May 2026 |
8-K: Other Events
On May 4, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) announced the primary endpoint was met in the VISTAS Phase 2b study evaluating volixibat, an investigational oral ileal bile acid transporter (“IBAT”) inhibitor, in patients wit... |
| 27 Apr 2026 |
8-K: Other Events
On April 27, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) announced the primary endpoint was met in the Phase 2b portion of the AZURE-1 study evaluating brelovitug, an investigational monoclonal antibody designed to bind hepatitis B... |
| 25 Feb 2026 |
8-K: Results of Operations and Financial Condition
–2026 expected global net product sales of $630 million to $650 million |
| 26 Jan 2026 |
8-K: Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure +1 more
- Adds brelovitug for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME designations to Mirum’s portfolio |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
J a n u a r y 2 0 2 6 Mirum Pharmaceuticals: Delivering High Impact Medicines for Rare Disease Exhibit 99.2 |
| 19 Dec 2025 |
8-K: Other Events
In November 2025, Mirum Pharmaceuticals, Inc. (the “Company”) announced that it received a Paragraph IV Certification Notice Letter (the “Notice Letter”) from Sandoz, Inc. (“Sandoz”), providing notification to the Company that Sandoz has... |
| 19 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), which is made and entered into as of December 18, 2025, among Mirum Pharmaceuticals, Inc., a Delaware corporation, and each of the several purchasers signatory hereto (each such purc... |
| 08 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
| 17 Nov 2025 |
8-K: Other Events
On November 17, 2025, Mirum Pharmaceuticals, Inc. (the “Company”) received a Paragraph IV Certification Notice Letter (the “Notice Letter”) from Sandoz, Inc. (“Sandoz”) providing notification to the Company that Sandoz has submitted an A... |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition
–Phase 2b VISTAS topline data expected second quarter of 2026 |
Loading...